Implementation of a pragmatic randomized trial of screening for chronic kidney disease to improve care among non-diabetic hypertensive veterans. by Peralta, Carmen A et al.
UCSF
UC San Francisco Previously Published Works
Title
Implementation of a pragmatic randomized trial of screening for chronic kidney disease 
to improve care among non-diabetic hypertensive veterans.
Permalink
https://escholarship.org/uc/item/9xw0f441
Journal
BMC nephrology, 18(1)
ISSN
1471-2369
Authors
Peralta, Carmen A
Frigaard, Martin
Rubinsky, Anna D
et al.
Publication Date
2017-04-12
DOI
10.1186/s12882-017-0541-6
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE Open Access
Implementation of a pragmatic randomized
trial of screening for chronic kidney disease
to improve care among non-diabetic
hypertensive veterans
Carmen A. Peralta1*, Martin Frigaard1, Anna D. Rubinsky1, Leticia Rolon2, Lowell Lo2, Santhi Voora3, Karen Seal1,
Delphine Tuot4, Shirley Chao1, Kimberly Lui1, Phillip Chiao1, Neil Powe4 and Michael Shlipak1
Abstract
Background: Whether screening for chronic kidney disease (CKD) can improve the care of persons at high risk for
complications remains uncertain. We describe the design and early implementation experience of a pilot, cluster-
randomized pragmatic trial to evaluate the feasibility, implementation, and effectiveness of a “triple marker” CKD
screening program (creatinine, cystatin C and albumin to creatinine ratio) for improving care among hypertensive
veterans seen in primary care at one Veterans Administration Hospital.
Methods/design: Non-diabetic hypertensive veterans age 18–80 without known CKD were randomized in clusters
determined by primary care provider (unit of randomization) into three arms. Usual care will be compared with two
incrementally intensified treatment strategies: (1) screen for CKD followed by patient and provider education or (2)
screen-educate plus a clinical pharmacist-led CKD and BP management program. The primary clinical outcome is
systolic blood pressure (BP) change from baseline. Secondary clinical outcome is BP control. The primary process
outcomes is triple marker screening (across three arms), and secondary process outcomes include use of inhibitors
of the renin-angiotensin system (ACE/ARB) overall and in persons with albuminuria, CKD recognition by PCP, use of
non-steroidal anti-inflammatory drugs (NSAIDs) and NSAID education by PCP. The design uses the Veterans Health
Administration electronic health record (EHR) to identify participants, deliver the interventions and ascertain study
outcomes. Assessment of the program implementation will use the Reach, Effectiveness, Adoption, Implementation,
and Maintenance (RE-AIM) framework. Study duration is 12 months.
Results: A total of 1,819 patients have been randomized within 41 provider clusters. The median age (interquartile
range) is 68 years (61–72), and 99% of participants are male. Approximately 16% are Black, and 5% Hispanic. In the
first 6 months of the trial, 434 triple marker screening tests have been ordered, and 217(50%) have been tested. A
total of 48 new CKD cases have been identified among those tested, for a preliminary yield of 22%.
Conclusion: We have successfully implemented a pragmatic protocol that uses the EHR to identify and characterize
eligible participants, deliver the intervention, and ascertain study outcomes with high rates of participation by
providers and patients. Results from this study can guide design of pragmatic trials in the field of CKD.
Trial registration: NCT02059408; Date or Registration: 1/17/2014.
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Background
The value of screening for chronic kidney disease (CKD)
remains uncertain. Several lines of evidence suggest that
screening may be a cost-effective strategy to reduce the
burden of CKD complications in certain high risk
groups. For example, CKD affects over 20 million adults in
the U.S. and is defined by an estimated glomerular filtration
rate (eGFR) <60 ml/min/1.73 m2 or an albumin-to-
creatinine ratio (ACR) ≥ 30 mg/g, two readily available clin-
ical tests [1, 2]. Persons with CKD are at high risk for com-
plications including cardiovascular events, progression to
end stage renal disease (ESRD), hospitalizations, cognitive
and functional decline, and premature death [3–6]. Early
detection and appropriate classification of CKD makes it
possible to optimize treatments for improving blood pres-
sure (BP) control, increase use of renin-angiotensin system
inhibitors (ACE or ARB) for persons with proteinuria, and
withdraw certain nephrotoxic medications [7]. CKD is
largely asymptomatic and it often remains undetected until
it has advanced; the vast majority of affected individuals are
unaware [8].
Despite its high prevalence, low recognition, high bur-
den of complications, and easy detection, there is no
agreement on a national systematic program to screen for
CKD in the United States. This is largely due to limited
evidence as to whether screening for CKD in high risk
persons improves outcomes. To our knowledge, no ran-
domized trials have evaluated the effectiveness of screen-
ing for CKD to improve care or to reduce adverse events.
Modeling studies have suggested that screening for CKD
may be cost-effective among persons with hypertension or
diabetes [9–12]. The United States Preventive Services
Task Force (USPSTF) has recently graded the effectiveness
of CKD screening as “I”, insufficient evidence to make a
recommendation [13]. Another impediment to assessing
the value of CKD screening is that, in practice, despite
many adults having serum creatinine measurements, and
most laboratories in the U.S. reporting corresponding
eGFR, documentation of CKD status in the medical rec-
ord remains low, suggesting that health care providers
may not recognize its presence or importance [14].
Moreover, reliance on serum creatinine alone to deter-
mine CKD status misclassifies persons [15]. International
guidelines recommend testing for albuminuria, in addition
to eGFR, to classify CKD [7]. Our group has shown that
cystatin C improves risk stratification of persons across a
wide range of creatinine based eGFR estimates [16]. We
have shown that a “triple-marker approach” using serum
creatinine, cystatin C, and the urine ACR significantly im-
proves CKD detection and risk classification for complica-
tions, compared with creatinine alone [15, 17]. We found
that persons with eGFRcys <60 ml/min/1.73 m2 and eGFR-
creat <60 ml/min/1.73 m2 and ACR ≥30 mg/g have the
highest risk for death and progression to ESRD [15].
Therefore, we believe that the triple marker approach allows
for efficient screening and risk stratification concomitantly.
We designed this pilot, cluster-randomized pragmatic
trial to evaluate the feasibility, implementation, and ef-
fectiveness of a “triple marker” CKD screening approach
for improving care among non-diabetic hypertensive vet-
erans seen in primary care at one Veterans Administra-
tion Hospital over 12 months. The three arms of our
trial will compare usual care to two incrementally inten-
sified treatment strategies: (1) screen for CKD followed
by patient and provider education and (2) screen-
educate plus a clinical pharmacist-led CKD and BP man-
agement program. Understanding the feasibility and
value of pharmacist BP co-management among hyper-
tensive persons with screen-detected CKD is important
because BP management by pharmacists or nurses has
been shown to be more effective than management by
physicians alone [18–20].
This report describes our rationale for and design of
the trial, as well as our experience in early implementa-
tion of the protocol. Communicating and disseminating
the implementation realities of pragmatic trials is critical
in CKD, as few of these studies are ongoing [21].
Trial design and methods
Trial overview
We designed the trial to have three groups: one usual care
arm, and two intervention arms (the screen & educate
arm, and the screen & educate + pharmacist arm) (Fig. 1).
The trial design takes advantage of the administrative
data in the Veterans health Administration (VHA) elec-
tronic health record (EHR) to identify non-diabetic Vet-
erans with hypertension who do not have a CKD
diagnosis and who are patients of the San Francisco VA
Health Care System (SFVAHCS) Medical Practice (MP)
Clinic (Primary Care). Study staff order triple-marker
labs (serum creatinine and cystatin C and urinary ACR)
via the EHR for all study participants in the intervention
arms who have an upcoming appointment with their pri-
mary care provider (PCP) in MP Clinic. PCPs receive
the triple-marker screening results and each patient’s
CKD status electronically to assist with categorizing each
patient by eGFR and ACR. We also give each PCP ap-
propriate, evidence-based treatment recommendations
for CKD care with each triple-marker lab result. These
are presented in the form of an electronic “research
note” in the EHR that requires a signed acknowledgment
by the PCP. The results are also mailed to patients in
both intervention arms, along with information on CKD
education materials developed by the National Kidney
Disease Education Program (NKDEP). The screen &
educate + pharmacist trial arm moves a step beyond the
screen & educate arm. PCPs in this arm are encouraged
to refer patients with screen-detected CKD to a primary
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care clinical pharmacist. The pharmacists use these ap-
pointments to address the use of ACE/ARB in persons
with albuminuria, provide education on CKD, and rec-
ommend NSAID avoidance with a scripted visit.
Objectives
Our aim was to address several gaps in knowledge that
currently hinder the ability to reach consensus on the
value of screening for CKD. First, we will determine the
yield (new cases detected) from a CKD screening pro-
gram using the triple-marker approach among non-
diabetic hypertensive veterans in primary care. We will
compare rates of creatinine, cystatin C and albuminuria
testing and use of NSAIDs, ACE/ARB, and blood pres-
sure (BP) levels across study arms. Among persons with
screen-detected CKD, we will compare the screen & edu-
cate arm and screen & educate & pharmacist on the use
of ACE/ARB in individuals with albuminuria, appropri-
ate CKD documentation in the medical record, NSAID
use, and BP levels. Finally, we will conduct a formal as-
sessment of the program implementation using the
Reach, Effectiveness, Adoption, Implementation, and
Maintenance (RE-AIM) framework [22, 23] (Table 1).
Setting
This study is being conducted within the primary care
clinics at the SFVAHCS an urban, academically affiliated
VA. These clinics include the medical practice (MP) and
the women’s clinic (WC), which are the primary care
clinics at the VA. We specifically designed this trial to
function within the framework of a Patient Aligned Care
Team Model (PACT), similar to a medical home model in
which PCPs practice within the context of a team of allied
health professionals including mental health, nursing,
nutrition, social work and pharmacy. The VA is the largest
health care system in US and the PACT model has been
in place in the primary care clinics across the VA nation-
ally since 2011. In particular, this study leverages the in-
volvement of the pharmacist on the VA PACT team.
Provider eligibility
There are two types of study subjects in this study: pro-
viders and patients. The attending PCPs are study subjects
(and are also the unit of randomization). All PCPs (MDs
and Nurse Practitioners) with active patient panels at
SFVAMC were eligible to participate (N = 70 PCPs). We
grouped the PCPs hierarchically by preceptor (attending)
and resident medical practice (MP) “units.” Preceptors (at-
tendings) practice independently, while residents are
grouped in pairs for cross-over, and they are supervised by
one of the attendings. A resident pair is considered one
“unit” and each individual attending is also considered
one unit or “team”. There were a total of 41 units/teams
available for randomization. The trial was approved by the
University of California Institutional Review Board. All
attendings provided written informed consent to partici-
pate. While obtaining consent, PCPs were given a list of
their eligible patients to facilitate exclusion procedures
(see below). Pharmacists are also study subjects and also
underwent informed consent procedures.
Fig. 1 Study design
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Patient identification, eligibility and characterization
For patients, inclusion and exclusion from the trial hap-
pened in three distinct stages. First, we used administra-
tive data from the VA Corporate Data Warehouse (CDW).
Individual patients were considered eligible for CKD
screening by this protocol and inclusion in the trial if they
met all of the following criteria: age 18–80 years; had a
visit with an eligible primary care provider at the
SFVAMC during the18 months prior to 5/31/2015; had
an outpatient diagnosis of hypertension (ICD-9-CM code
401.1 or 401.9 in Outpat_VDiagnosis) in the period 5/16/
2010-5/15/2015; did not have an outpatient diagnosis of
diabetes mellitus (ICD-9-CM code beginning “250.” in
Outpat_VDiagnosis) for any date through 5/31/15; and
did not have an outpatient diagnosis of chronic kidney
disease (ICD-9-CM code beginning “585.” in Outpat_V-
Diagnosis) for any date through 5/31/15. We defined diag-
nosed CKD without consideration of creatinine or ACR in
the laboratory section of the medical record, since work
from our group and others has shown that awareness and
recognition of CKD is extremely low, even among persons
with documented reduced eGFR [14, 24]. We excluded
persons who need specialty care: kidney transplant, preg-
nancy or eGFR < 15 ml/min/1.73 m2.
To further characterize patients, we assessed history of
coronary artery disease (ICD-9-CM 410–414.99; ICD-10-
CM I20-I25), congestive heart failure (ICD-9-CM 428.XX;
ICD-10-CM I50.XX)], medication use based on fills at a VA
pharmacy or paid for by VA, or non-VA medications
reported by a patient, within six months prior to
randomization, blood pressure levels within 1 year prior to
randomization, outpatient laboratory data within 2 years
prior to randomization (creatinine, urinary albumin) from
VA electronic medical record data [CDW diagnoses,
laboratory, non-VA medication, and vital status data, and
Managerial Cost Accounting laboratory and pharmacy data].
To evaluate the fidelity of the EHR as data source for
this study, we validated the inclusion criteria and three
major relevant comorbidities: coronary artery disease,
cerebrovascular disease and congestive heart failure with
chart review. Two trained nephrologists (L.R. and S.V.)
blinded to diagnoses obtained from the EHR reviewed
50 random charts to validate ICD-9-CM based defini-
tions. A third reviewer (C.P.) assessed charts where there
was disagreement. We used criteria as previously speci-
fied in a validated CKD registry [25].
Additional patient exclusion procedures
PCPs had the option to exclude any patient that met ex-
clusion criteria or who they deemed not appropriate for
CKD screening. We provided PCPs a preliminary list of
eligible patients and given the opportunity to exclude
patients based on the criteria if life expectancy is <1 year
or patients had a diagnosis of dementia, severe vision
Table 1 The six domains of the RE-AIM framework and the application to this trial
RE-AIM domain Measure of interest Ascertainment modality
Reach of target (individual level) Identification of Patients for Inclusion and
Exclusion
Characteristics of enrolled vs. excluded or opt
out
Patient characteristics by arm
Proportion who agree to participate
Research coordinator log
Database query
Chart review
Reach of target (setting/organization) Acknowledgement of research note by PCP
Result Letters Sent
Database Query
Coordinator Log
Effectiveness (individual level) Proportion Screened
Yield of Testing
Proportion who attend pharmacy visit
BP level
NSAID use
ACE/ARB use
CKD recognition
Questionnaire
Database Query
Pharmacist log
Chart Review
Adoption by target
(setting/organization level)
Perceived work flow
Satisfaction with program
Structured Interviews
Email Survey
Implementation
(setting/organization level)
Fidelity monitoring
Verify use of treatment algorithm by
pharmacist
Structured interviews and questionnaire
Pharmacist log
Maintenance/
Sustainability (provider)
Satisfaction with program Email questionnaire
Maintenance/
Sustainability (patients)
BP control, use of NSAIDs, ACE/ARB after
cessation of intervention
Database query
Resources Time by pharmacist
Nephrology consultations
Costs
Time logs
VA costs
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impairment, severe mental illness or substance abuse
that significantly interferes with receiving care or inclu-
sion in the study is not appropriate (e.g. due to cognitive
dysfunction or severe anxiety). Patients were also ex-
cluded from the trial if they had heart failure identified
by ICD-9-CM 428.0, and a reduced ejection fraction
confirmed by echocardiography(<40%) within 5 years.
Patient consent process
The study received waivers of informed consent and
Health Insurance Portability and Accountability Act
(HIPAA) authorization for obtaining limited data to
identify patients for inclusion/exclusion. Following
randomization of provider teams, eligible patients re-
ceived a copy of the UCSF informed consent document
and an information letter by mail, explaining the proto-
col and notifying them that orders for CKD screening
would be submitted prior to their next scheduled ap-
pointment. Participants were given the option to opt-out
of this study at any time by calling or mailing the card
back. After the initial letter, an additional letter was sent
to eligible patients of providers randomized to the usual
care arm to clarify that they would remain eligible for
CKD screening, by request, from their PCP. Participants
who did not opt out by 6 weeks followed the mailing
were included in the study.
Randomization and blinding
Randomization occurred at the level of the MP or WC
“unit” or “team” in order to avoid contamination across
trial groups that may occur if patients in multiple arms
are managed within the same team. We chose to block-
randomize by number of patients per team and by attend-
ing vs. resident in order to balance these characteristics
across study arms. Patients are linked to the PCP using
the EHR, and were assigned to a trial arm based on their
provider team’s assignment. PCPs are not blinded to treat-
ment assignment after randomization since they facilitate
the intervention arms. The analysts will remain blinded
throughout the trial and data analyses.
Description of study interventions
Prior to the beginning of this trial, all clinicians at the
SFVAHCS had the opportunity for education on the inter-
national CKD guidelines in the form of a Grand Rounds.
Clinicians were informed of this trial by the PI during pro-
vider staff meetings. All providers have access to educa-
tional materials such as UptoDate and the UCSF library.
Usual care
Following enrollment, PCPs randomized to usual care
continue to manage the patients as usual. No systematic
screening for CKD among non-diabetics is performed at
SFVAMC. Referral to the PACT pharmacist remains an
option, as this is part of usual care within the PACT
model. Triple-marker screening for CKD is clinically avail-
able, and providers in the usual care arm are able to order
these lab tests if deemed appropriate.
Intervention 1 (screen & educate)
We designed each intervention design to be feasible and
to follow the usual workflow. For included patients, we
identify their upcoming appointments using CDW data
on a weekly basis. Study staff place orders for a serum
creatinine, serum cystatin C and urinary albumin to cre-
atinine ratio. All tests are performed locally at the clin-
ical lab. Serum and urine creatinine are measured by the
Jaffe method, cystatin C is measured using the particle-
enhanced cystatin C assay from Gentian [26], and the
urine albumin by nephelometry. Tests are ordered prior
to the next scheduled visit with their assigned PCP. The
study staff ensures that the PCP receives the test results,
along with the CKD stage (or no CKD), and a summary
of KDIGO guidelines for BP management appropriate
for the specific CKD stage in the form of an electronic
note which the PCP has to co-sign. These electronic
notes also include a reminder to counsel on NSAID use,
and the use of ACE/ARB in persons with albuminuria.
(Additional file 1) All participating patients in the inter-
vention arm receive notification of test results by mail.
All persons with screen-detected CKD and their PCPs
will receive educational materials available from the Na-
tional Kidney Disease Education Program (NKDEP) as a
web link on the note or letter they receive by mail.
Intervention 2 (screen-educate-active BP management by
clinical pharmacist)
In addition to the screening and education as above,
providers randomized to this arm will have the option to
refer patients with screen-detected CKD to be co-
managed by a clinical pharmacist. The clinical pharma-
cists at the VA hold doctoral degrees (PharmD) and they
are active members of the care teams, as described
above. The pharmacists already provide consultation for
BP management at SFVAMC when referred by PCP. At
SFVAMC, pharmacists are authorized to initiate therapy,
adjust doses, monitor complications and order labs tests,
under the supervision of the attending physician. Spe-
cific to this study, when the triple marker screen identi-
fies CKD, research staff will notify providers through a
note in the EHR that pharmacist co-management is
available for their patient and they can refer to the
pharmacist through the electronic consult request for
CKD and hypertension management and education.
Physicians in the other arms may still refer to pharmacy
for other indications, but they are not notified of the
availability of this service. Upon receipt of referral, the
pharmacist schedules a series of appointments aimed at
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education on CKD and its complications, as well as edu-
cation on avoiding NSAID use. The visit also focuses on
BP control and initiation or up-titration of ACE/ARB
therapy in persons with albuminuria. At each visit, the
pharmacist measures and records two seated BP read-
ings, and will perform medication inventory and review
adherence. Education regarding diagnosis of CKD is
based on previously designed materials provided by
NKDEP that include lifestyle modification. Management
follows evidence-based algorithms with the goal of
achieving BP <140/90 mmHg and using ACE or ARBs
for persons with albuminuria. Lower BP goals can be re-
quested by the PCP. Initially, pharmacist follow-up visits
are every 2 weeks, and once a patient’s BP is controlled
on2 or more consecutive visits, follow-up ends. The
pharmacist orders a chemistry panel to monitor for
hyperkalemia or rising creatinine if ACE/ARB is initiated
or uptitrated. If a patient is found to have eGFR <30 ml/
min/1.73 m2, were commend nephrology referral for
pre-dialysis care. At the end of 12 months, the pharma-
cist will stop following patients. To verify the fidelity of
the educational intervention, the pharmacist presents
several randomly chosen cases to the nephrologist in-
volved in algorithm design. The pharmacists collabo-
rated on creating the CKD visit algorithm along with
study MDs (Additional file 2).
Outcomes of interest
We will ascertain: (1) patient completion of ordered triple
marker tests; (2) yield of testing, calculated as the propor-
tion with new CKD cases identified among those tested;
(3) acknowledgement of CKD results and CKD recogni-
tion by PCP; (4) use of ACE/ARB; (5) NSAID education
and use, and (5) BP levels, estimated as change in blood
pressure from enrollment to the end of the 12-month fol-
low up period as a continuous outcome, from the CDW.
The primary clinical outcome is systolic blood pressure
level change from baseline. BP measures from the clinical
record will be ascertained no more than quarterly. We will
also consider the dichotomous outcome “achieved sus-
tained BP control”, defined as BP <140/90 mmHg in ≥ two
consecutive visits during the trial. The primary process
outcome of this trial is triple marker screening using cre-
atinine, cystatin C and ACR. Secondary process outcomes
include CKD recognition and appropriate risk stratifica-
tion by PCP, ACE/ARB use overall and in persons with al-
buminuria, NSAID use, NSAID education by PCP to
patient. ACE or ARB use and NSAID use will be deter-
mined by ACE/ARB prescription from enrollment to 12-
month follow-up, which will be ascertained from phar-
macy data files quarterly. Documentation of CKD in EHR
will be ascertained by using diagnostic codes and chart re-
view. We will also compare CKD status at the end of the
study using administrative codes vs. review of PCP notes.
NSAID education from PCP to patient will be assessed by
chart review. In exploratory analyses, we will record all
follow up measures of serum creatinine, cystatin C and
ACR in order to assess renal function decline or recovery.
Sample size and power
All power calculations were performed using Stata version
11.2. Calculations were performed for 80% power assuming
a two-tailed alpha level of 0.05 and intraclass correlation
coefficient (ICC) of 0.025 to account for the clustering. We
determined baseline rates/levels in usual care from CDW,
and hypothesized that persons in the intervention arms
would have lower BP levels and improved processes of care
compared with usual care. For comparisons across the
three arms, assuming approximately 450 persons per arm,
for differences in systolic blood pressure (SBP) change, we
will have 80% power to detect a difference ≥1.82 mmHg for
SBP if we include 600 persons per arm, and ≥2.2 mmHg if
we have 300 persons per arm. We powered the study for
change in blood pressure levels.
Results
Reach of target at the patient level
Patient identification and participation
We identified 2,293 patients at the SFVAMC who met
initial criteria. A total of 114 were either assigned to the
provider who did not consent or to a study physician
(M.S) and were thus excluded. Providers excluded an
additional 138 patients after reviewing their patient list.
We identified 36 patients with an EF < 40%, but 9 of these
patients had already been excluded by their PCP, and 2
persons who had died since the data pull, and who had
not previously been excluded by PCP. Since mailing of the
information letters to 2012 patients, we received 141 tele-
phone calls. Of these, 73 called to opt out. The rest of the
calls reflected interest in the program and wanting to
participate or alerting us to upcoming appointments. We
have had only 1 phone call from a veteran stating that
receiving the information letter caused great anxiety. We
excluded a total of 193 persons who opted-out or had no
available address and no other contact information. A
total of 1,819 patients are included in this trial (Fig. 2).
The EHR administrative data accurately identified
persons for inclusion and exclusion in this trial.
Among 50 charts reviewed, one person had been liv-
ing at the nursing home and had incomplete informa-
tion to assess all the comorbidities. Of the remaining
49 charts, 45 (92%) had confirmed hypertension by
the reviewers, and agreement for diabetes status was
100%. Agreement of EHR and physician review is
shown in Table 2. While we found good agreement
for coronary artery disease, we found less agreement
for cerebrovascular disease and congestive heart
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failure, where chart review was more likely to identify
these diagnoses that the EHR.
Participant characteristics
Overall, the median age (interquartile range) of 1, 819 in-
cluded participants was 68 years (61–72), and only 8 were
female. Approximately 16% are Black, and 5% Hispanic.
We have found that 18% of participants have active pre-
scription for NSAIDS, and 35% were on ACE/ARB at study
start. We found that the majority of participants had a prior
serum creatinine tested, and about 50% of participants had
a prior urinary dipstick result in the chart. Less than 10% of
persons had an albumin to creatinine ratio (ACR) tested
prior to randomization. Characteristics of participants in-
cluded in the study vs. those were excluded are presented
in Table 3. Overall, excluded patients were similar in age,
demographics, and comorbidities. Excluded persons were
less likely to be using an anti-hypertensive medication, were
somewhat less likely to have prior testing for proteinuria,
and had a higher prevalence of drug use disorders. In the
period between data pull and randomization, a total of N =
34 patients had new diagnoses of diabetes, and N = 11 had
a new diagnosis of CKD among participant included in the
study, but these were relatively evenly distributed by arm.
Fig. 2 Consort diagram for patient inclusion
Table 2 Agreement between EHR and chart review for relevant comorbidities
Chart Review
Overall Agreement Kappa
(95% CI)
PPA*
(95% CI)
NPA*
(95% CI)
Coronary Artery Disease 96% 0.883 91% 97%
(0.724-1.000) (86-100%) (86-100%)
Cerebrovascular Disease 88% 0.188 20% 96%
(-0.225-0.601) (0.5-72%) (84-99%)
Congestive Heart Failure 92% 0.456 50% 96%
(0.006-0.905) (7.0-93%) (85-100%)
*PPA Positive Percent Agreement (mathematically equivalent to sensitivity), NPA Negative Percent Agreement (mathematically equivalent to specificity)
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Reach of target at provider level
A total of 41 provider teams (representing 70 individual
providers) were randomized. Two PCPs left the practice
after they consented to participate and were randomized,
but before testing was implemented, potentially affecting
179 patients. As per clinical workflow, these patients will
be reassigned to an appropriate provider with availability,
who may or may not have been randomized to the same
trial arm as the original provider. In addition, 14 residents
graduated, and these patients are expected to be reas-
signed to new trainees or existing providers. Changes in
resident panels may affect 345 patients.
Effectiveness in implementation: early experience in
proportion screened and yield of testing
In the first 6 months of the trial, 434 discrete patients
with appointments have been identified in the interven-
tion arms, and orders for triple marker screening have
been entered. Of these, 217(50%) have been tested as of
September 15, 2016. We have identified 48 new CKD
cases among those tested (22%). We have identified two
cases of acute kidney injury.
Early adoption
To date, we have not had any complaints from the pro-
viders about the study. A total of 217 research notes
have been sent to PCP for co-signature. The P.I. has
attended two staff meetings after protocol implementa-
tion to answer questions about the study.
One meeting with the pharmacists has occurred after
protocol implementation to ensure fidelity of the pharmacy
Table 3 Characteristics of veterans randomized, compared with
those excluded
Randomized
(N = 1819)
Excluded
(N = 193)
Variable N (%) N (%) p-value
Gender 0.877
Female 8 (0.4%) 1 (1%)
Male 1811 (100%) 192 (99%)
Age 0.242
26-50 169 (9%) 14 (7%)
51-60 288 (16%) 22 (11%)
61-70 805 (44%) 90 (47%)
71-80 557 (31%) 67 (35%)
Race/Ethnicity 0.575
White 1009 (55%) 104 (54%)
Black 298 (16%) 27 (14%)
Asian/Pacific Islander 150 (8%) 14 (7%)
Amer. Indian 11 (1%) 1 (1%)
Hispanic 92 (5%) 10 (5%)
Missing 259 (14%) 37 (19%)
CKD 0.477
No 1808 (99%) 191 (99%)
Yes 11 (1%) 2 (1%)
Ischemic Heart Disease 317 (17%) 37 (19%) 0.545
Congestive Heart
Failure (core)
108 (6%) 7 (4%) 0.189
Cardiomyopathy 29 (2%) 1 (1%) 0.241
Cerebrovascular Disease 167 (9%) 13 (7%) 0.258
Diabetes Mellitus 34 (2%) 3 (2%) 0.757
Hyperlipidemia 1163 (64%) 124 (64%) 0.931
Hypertension (common) 1794 (99%) 191 (99%) 0.698
Chronic obstructive
pulmonary disease
and bronchiectasis
143 (8%) 12 (6%) 0.415
Tobacco Use Disorder 496 (27%) 48 (25%) 0.476
Drug Use Disorder 288 (16%) 42 (22%) 0.034
Alcohol Use Disorders 484 (27%) 46 (24%) 0.406
Mental Health Disorders 893 (49%) 91 (47%) 0.608
Any Hypertension Meds 1288 (71%) 116 (60%) 0.002
Beta Blockers 498 (27%) 37 (19%) 0.014
Ace Inhibitors 505 (28%) 43 (22%) 0.104
Angiotensin Receptor
Blockers
134 (7%) 10 (5%) 0.263
Aspirin 250 (14%) 16 (8%) 0.033
Statins 793 (44%) 63 (33%) 0.003
NSAID 333 (18%) 25 (13%) 0.064
Table 3 Characteristics of veterans randomized, compared with
those excluded (Continued)
Urine – Dipstick Prior to Screening <0.0005
Neg (<10 mg/dl) 810 (45%) 61 (32%)
Trace (10-20 mg/dl 7 (0%) 0 (0%)
1+ (30 mg/dl) 62 (3%) 15 (8%)
2+ (100 mg/dl) 41 (2%) 6 (3%)
3+ (300-500 mg/dl) 2 (0%) 2 (1%)
Missing 897 (49%) 109 (56%)
Albumin: Creatinine
Ratio Tested
172 (9%) 7 (4%) 0.007
Creatinine Tested Prior 1658 (91%) 160 (83%) <0.0005
Creatinine (mean, SD) 1.0 (0.2) 1.0 (0.2) 0.671
Cystatin C Tested Prior 83 (5%) 7 (4%) 0.550
Systolic Blood Pressure 139(18) 139(18) 0.87
Diastolic Blood Pressure 81(11) 81(9) 0.49
All Comorbidites were ascertained by the use of administrative data. Tests
“prior” means done before trial started. SBP and DBP are ascertained as mean
of values within 6 months prior to randomization date
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visit flow. All the participating pharmacists (3) were able to
verify the study procedures at the meeting.
Statistical analysis considerations based on
implementation experience
The primary analyses will follow intention to treat princi-
ples. We have designated a priori sensitivity analyses will
include “as treated” analyses, in order to understand the
impact of patients changing physicians who may have
been randomized to a different arm initially.
Discussion
As CKD continues to represent a large burden in the U.S.,
understanding the value of systematic, early screening for
CKD in targeted populations is paramount. In this report,
we describe the rationale, design and initial implementa-
tion experience of a pilot pragmatic randomized trial to
address this question. This report describes lessons
learned from one of the few ongoing pragmatic random-
ized trials in the field of CKD. We have successfully imple-
mented a protocol that uses the EHR to identify and
characterize eligible participants, deliver the intervention,
and ascertain study outcomes, consistent with the Insti-
tute of Medicine goals for a “learning health care system”.
Our study is largely pragmatic, according to the PRECIS
criteria for rating of trials [27]. We have also found that,
thus far, there are high rates of participation by providers,
the opt-out rate by patients was low, and a high propor-
tion of patients with appointments have followed through
with testing after the tests are ordered. Moreover, we
learned several important “real-world” lessons that are
likely to affect this study and design of future pragmatic
trials in the field of CKD, including provider turnover, in-
formed consent barriers, and data science considerations.
PCP and pharmacist participation in this study have
been crucial. We believe that the frequent face-to-face
communication between study staff and PCP prior to the
study was an important step to ensure stakeholder en-
gagement. The PI of this study (C.P.) had weekly meetings
with the medical practice leadership during the planning
phase to ensure the trial was designed to follow PCP
workflow. We spent several weeks imbedded in the clinics
to tell providers about the study and understand work-
flows. Since we took the time to gather accurate lists of
their patients to be included and excluded, we reduced the
amount of effort needed to identify patients who may not
be appropriate for CKD screening or to participate in re-
search. We engaged the pharmacists as stakeholders in
building the intervention, which ensured it followed work-
flow, was feasible, and to ensure fidelity of the study
procedures.
The finding that there is significant provider and patient
turnover may affect the results of a pragmatic study ran-
domized by team as it can lead to reduced protocol fidelity
and contamination between arms. In the future, a larger
pragmatic trial of CKD screening will need to randomize by
clinic, rather than by provider to reduce contamination. In
the case of this pilot, this was not feasible due to limited re-
sources. Therefore, we have planned a priori analyses that
will include intention-to-treat and as-treated. The ideal
study would enroll patients on a “rolling” basis. For ex-
ample, patients could be enrolled at the time they are iden-
tified as meeting inclusion criteria and having a scheduled
appointment with the PCP. This strategy would allow the
flexibility of changes in clinic assignments, and would en-
sure inclusion of patients still engaged with the system.
This was not feasible in this study because we had to obtain
informed consent via a mass mailing with a subsequent opt
out period, making it very difficult to incorporate the many
schedule changes that happen in clinical practice over this
duration. We strongly advocate that pragmatic studies with
very low risk interventions request a waiver of individual in-
formed consent and perhaps only require that all patients
are informed about the study and have the option to opt
out by placing flyers in the clinic, or mailing short informa-
tion pamphlets (rather than the full consent document)
well before enrollment begins.
Finally, we would like to emphasize the critical im-
portance of the data scientists in order to implement
this EHR-based/reliant study successfully. We spent
considerable time and resources building a custom
database for study management. Moreover, an experi-
enced data expert was necessary to obtain all the in-
formation from CDW and ensure accurate PCP
assignment for each patient. The data scientists work
as part of the team including the PI and the clinicians,
in order to ensure accurate data use and to understand
the clinical considerations. Future studies that rely on
the EHR to deliver interventions must include a team
with multi-disciplinary expertise and frequent meet-
ings, and clinicians who can validate the data.
Conclusions
In summary, we describe a successful implementation of a
pilot RCT to evaluate the effectiveness of CKD screening
to improve processes of care among hypertensive veterans
without diabetes. Results from this study can guide design
of pragmatic trials in the field of CKD.
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